Altimmune
ALT
21 hedge funds and large institutions have $3.24M invested in Altimmune in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 10 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
95% more capital invested
Capital invested by funds: $1.66M → $3.24M (+$1.58M)
1.32% more ownership
Funds ownership: 9.22% → 10.55% (+1.3%)
8% less call options, than puts
Call options by funds: $669K | Put options by funds: $727K
9% less funds holding
Funds holding: 23 → 21 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$780K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$773K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$380K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$172K |
| 5 |
Squarepoint
New York
|
+$101K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$709K |
| 2 |
Renaissance Technologies
New York
|
-$254K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$175K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$82K |
| 5 |
VF
Virtu Financial
New York
|
-$34K |
ALT Hedge Fund Activity: Q1 2019 in Review
21 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q1 2019, worth a combined $3.24M — up 95% from $1.66M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ALT and 8 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 6 added.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $780K. The largest seller was Sabby Management, exiting entirely with an estimated $709K sold.
- 21 institutional investors held Altimmune (ALT) as of Q1 2019, down from 23 in Q4 2018.
- Funds reported $3.24M of Altimmune stock for Q1 2019, up 95% quarter-over-quarter.
- 8 funds opened new Altimmune positions in Q1 2019 and 10 closed out, a net change of -2 holders.
- The largest Altimmune buyer in Q1 2019 was Hudson Bay Capital Management, an estimated $780K added.
- The largest Altimmune seller in Q1 2019 was Sabby Management, an estimated $709K sold.
Based on aggregated 13F filings for Q1 2019.